PIR International is pleased to announce the placement of Giles Brown as SVP of Chemistry at Amphista Therapeutics.

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, is applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the lives of patients with severe diseases including cancer and central nervous system diseases. Giles joins Amphista with over 20 years’ experience in medicinal chemistry during which he contributed to the discovery and development of fifteen preclinical candidates, of which seven successfully entered clinical trials. He joins Amphista from Dunad Therapeutics where he served as Senior Vice President of Chemistry focusing on the discovery of molecular glues. Prior to this, Giles held senior roles at OMass Therapeutics and Sosei Heptares. He holds a PhD from the University of Bristol and his MBA from Henley Business School, UK.

Nicola Thompson, Chief Executive Officer of Amphista Therapeutics stated: “Giles is an exceptional chemist and leader with an outstanding track record of drug discovery. His appointment to Amphista reflects the strength of the innovative approach we are taking in TPD to deliver a new generation of therapeutic molecules. We very much look forward to working with Giles to further advance our technology and drug discovery pipeline.”

Giles Brown, Senior Vice President of Chemistry of Amphista Therapeutics, added: “Amphista’s differentiated, next-generation, approach to targeted protein degradation, and its proprietary platform technology, offer a unique opportunity for the discovery of novel, differentiated medicines. I am excited to be joining a team of innovators to advance the Company’s chemistry-led strategy and progress the pipeline to deliver potential medicines for many hard-to-treat diseases.”

Click here to read more: Amphista Therapeutics Appoints Dr. Giles Brown as Senior Vice President of Chemistry – Amphista Therapeutics